Chronic lymphocytic leukemia: an updated review.
OBJECTIVE
To review recent advances in the pathogenesis, biology, diagnosis, and management of chronic lymphocytic leukemia (CLL).


METHODS
A literature search restricted to English-language articles, abstracts, book chapters, and reports published between 1975 and 1993 was conducted both electronically using MEDLINE and CANCERLIT and manually using the bibliographies of the electronically retrieved data base. Of approximately 1,000 publications identified for analysis, 233 were selected as representative of important advances in CLL.


RESULTS
The last 10 years have witnessed renewed interest in the biology and treatment of CLL, a disease long viewed by clinicians as following an indolent course and perceived by investigators as uninspiring. This interest, based on advances in understanding the lineage and biology of CLL and on the advent of new and more efficacious chemotherapeutic agents, has led to improvements in patient survival and, for the first time, to complete remissions (CRs) in large subsets of patients. As we learn to use these agents better, especially in combination chemotherapy, alternative therapeutic modalities, are being vigorously pursued, including high-dose ablative chemotherapy with allogeneic or autologous bone marrow transplantation (BMT) rescue and the use of powerful tumor-cell target-specific immunoreagents. These therapeutic advances, coupled with the recent availability of molecular probes to ascertain objectively minimal remnant disease posttreatment, provide a basis for developing and assessing ever more efficacious and potentially curative treatment strategies for the management of this disease.


CONCLUSIONS
For the first time since the original 1924 monograph by Minot and Isaacs, the cure of subsets of patients with CLL appears not to be an unreasonable goal.
Faguet
G B
GB
Department of Medicine, Medical College of Georgia, Augusta.
D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003131:Combined Modality Therapy; D016147:Genes, Tumor Suppressor; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000922:Immunotoxins / Q000627:therapeutic use; D007239:Infections / Q000150:complications; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000209:etiology / Q000235:genetics / Q000628:therapy; D016609:Neoplasms, Second Primary; D009503:Neutropenia / Q000139:chemically induced; D009857:Oncogenes; D016499:Radioimmunotherapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014777:Virus Diseases / Q000150:complications
D007155:Immunologic Factors; D000922:Immunotoxins